Last update 17 Apr 2025

Telomelysin

Overview

Basic Info

Drug Type
Oncolytic virus
Synonyms
Suratadenotureb, Suratadenoturev, Telomerase-specific Type 5 Adenovirus OBP-301
+ [1]
Action
inhibitors
Mechanism
Telomerase inhibitors
Originator Organization
Inactive Organization
Drug Highest PhasePhase 2
First Approval Date-
Regulation-
Login to view timeline

Structure/Sequence

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Adenocarcinoma of EsophagusPhase 2
United States
25 Apr 2024
Adenocarcinoma of EsophagusPhase 2
United States
25 Apr 2024
Metastatic Gastroesophageal Junction AdenocarcinomaPhase 2
United States
25 Apr 2024
Metastatic Gastroesophageal Junction AdenocarcinomaPhase 2
United States
25 Apr 2024
stomach adenocarcinomaPhase 2
United States
25 Apr 2024
stomach adenocarcinomaPhase 2
United States
25 Apr 2024
Recurrent Squamous Cell Carcinoma of the Head and NeckPhase 2
United States
03 May 2021
Gastroesophageal junction adenocarcinomaPhase 2
United States
09 May 2019
Esophageal CarcinomaPhase 2
United States
-28 Jan 2019
Metastatic melanomaPhase 2
United States
22 Dec 2016
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
17
epdnvltrfk = yotykejoii wgxuiybxiv (brsdwfjlgg, ouzlsciuno - fpvkhwzzgp)
-
25 Jun 2024
Phase 1
20
rftpspfcxg(hdgpszrqbp) = cvndhmjoru rtnyahwxbg (barxxcfmeq )
Positive
01 Jul 2023
Phase 2
16
Pembrolizumab+Telomelysin
qtntjssxcm(kkulezkjpj) = Toxicity attributed to OBP-301 included grade 2 fatigue/weakness (25%), grade 2 fever (18.7%), and a single incidence each of grade 2 nausea, anemia, grade 3 melena, and grade 4 diabetes mellitus (6.25%). njbyofjvhm (yabxuxrgid )
Positive
31 May 2023
Phase 1
22
xucnriufuw(gqfxfmhnnm) = tqmlcscdbq lyijhhrxyy (hfhbeqfwhu )
Negative
14 Apr 2023
Phase 2
1
gqgaumzfqa(sligidigwt) = cfktngaiig jthluhttod (stdjjsfsdo, vlzdkrfphr - czkxtyjkpf)
-
11 Jan 2023
Phase 1
13
radiotherapy+OBP-301
pjsgcroced(vjwtsvsulv) = zrecwawgub nkikwhoret (zvjyuijmlw )
Positive
01 Aug 2021
Phase 1
13
ctooolrnwp(qgfubcvvht) = mmzqecbsyx zlhwkneoby (tjtlocczoz )
Positive
29 Jan 2019
Phase 1
-
arcymlqwtm(nmxugacooa) = dorsuoeilj jidxmhlfra (xqwvwyugoi )
-
20 May 2014
Phase 1
Advanced cancer
hTERT expression
16
Telomelysin (OBP-301) 1×10^10 viral particles
rhcfmppzpq(lzfzuwfumi) = Common grade 1 and 2 toxicities included injection site reactions (pain, induration) pqtctvtbop (lxmaleuaxh )
Positive
01 May 2009
Telomelysin (OBP-301) 1×10^11 viral particles
Phase 1
9
jhafzzacxl(daiqvqzddl) = bruising (22%) vvbcdyerwm (epmivdnitp )
-
20 May 2008
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free